Insider Purchases: Inside the Buy
Tag: CEO Buys
Enphase Energy: The Comeback Nobody Believed (But the CEO Keeps Buying)
Enphase Energy fell hard after its solar boom—but the CEO keeps buying, institutions still dominate the float, and shorts are piled in. Here’s why ENPH might be starting to sync back in—and what investors should really watch. 🌞🔋
CEO Buys Shares of International Paper: Toilet, Shredded, or Stationery?
International Paper is mid-divorce, mid-restructuring — and its CEO just bought $2M of stock. A messy, event-driven value play with real risk and real conviction.
Can XOMA Become Royalty? The CEO, BVF Partners, and Morgan Stanley Think So!
XOMA Royalty doesn’t run clinical trials—it collects royalties. With a $2.5M CEO insider buy, heavyweight institutional backing, and improving cash flow, this biotech quiet achiever may be turning into something… royal.
Insiders Buy Shares Again; Can Energizer Regain Power?
Energizer insiders keep loading up on shares while institutions hold more than the float. Meanwhile, guidance dips and tariffs bite. Is ENR a contrarian deep-value gem ready to recharge — or a battery running low? Here’s the fun, funny breakdown. 🔋🐰
Insiders Purchase Shares of Goosehead Insurance — Should You Buy, Duck, or Just Take a Gander?
Insiders are loading up on Goosehead Insurance shares — and institutions can’t get enough. With strong growth but real risks, is this goose ready to fly… or cooked? Here’s the fun, smart breakdown. 🪿📈🔥
Insiders Buy Shares of Corsair Gaming: Is Management On Deck To Deliver?
Insiders and institutions are piling into Corsair Gaming (CRSR) just as revenue, margins, and product launches accelerate. With a new CFO, a strong Q3, and a massive PC upgrade cycle on deck, this stock could respawn in a big way — if management delivers.
Insiders Are Buying Bath & Body Works — Will BBWI Clean Up Its Act or Is It Just Soap Opera?
Bath & Body Works stock has plunged—but insiders, institutions, and some analysts still can’t resist the scent. Is BBWI a deep-value revival story or just investor soap opera? Let’s investigate—fun included. 🧼📉📈
Fox Factory: Left for Roadkill or Setting Up a Suspension Rebound?
Fox Factory (FOXF) went from high-flyer to face-plant, trading over 90% below its peak — yet the CEO and big institutions keep buying. Is this a stealth value opportunity or a suspension story that never quite rebounds? Let’s dig in, with jokes and numbers.
Biohaven Just Went Through Hell — But Its CEO and Directors Still See an Angel
Biohaven’s stock plunged after a brutal FDA rejection — but insiders didn’t blink. They bought millions of dollars’ worth of shares, doubled down on their pipeline, and kickstarted a leaner, more focused strategy. Bold turnaround play or biotech heartburn waiting to happen? Here's the FUNanc1al deep dive.
CEO Buys Shares of Roper Technologies: Knows the Ropes or On the Ropes?
A massive insider buy, a $3B share repurchase program, soaring cash flow, and institutions owning nearly the entire float. Is Roper Technologies signaling deep value—or just tugging on your curiosity rope?